Inhibitory effect of TNF-alpha on the intestinal absorption of galactose

J Cell Biochem. 2007 May 1;101(1):99-111. doi: 10.1002/jcb.21168.

Abstract

Sepsis is a systemic response to infection in which toxins, such as bacterial lipopolysaccharide (LPS), stimulate the production of inflammatory mediators like the cytokine tumor necrosis factor alpha (TNF-alpha). Previous studies from our laboratory have revealed that LPS inhibits the intestinal absorption of L-leucine and D-fructose in rabbit when it was intravenously administered, and that TNF-alpha seems to mediate this effect on amino acid absorption. To extend this work, the present study was designed to evaluate the possible effect of TNF-alpha on D-galactose intestinal absorption, identify the intracellular mechanisms involved and establish whether this cytokine mediates possible LPS effects. Our findings indicate that TNF-alpha decreases D-galactose absorption both in rabbit intestinal tissue preparations and brush-border membrane vesicles. Western blot analysis revealed reduced amounts of the Na+/glucose cotransporter (SGLT1) protein in the plasma membrane attributable to the cytokine. On the contrary, TNF-alpha increased SGLT1 mRNA levels. Specific inhibitors of the secondary messengers PKC, PKA, the MAP kinases p38 MAP, JNK, MEK1/2 as well as the proteasome, diminished the TNF-alpha-evoked inhibitory effect. LPS inhibition of the uptake of the sugar was blocked by a TNF-alpha antagonist. In conclusion, TNF-alpha inhibits D-galactose intestinal absorption by decreasing the number of SGLT1 molecules at the enterocyte plasma membrane through a mechanism in which several protein-like kinases are involved.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anthracenes / administration & dosage
  • Anthracenes / pharmacology
  • Blotting, Northern
  • Blotting, Western
  • Cell Membrane / drug effects
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Enzyme Inhibitors / pharmacology
  • Galactose / antagonists & inhibitors*
  • Imidazoles / administration & dosage
  • Imidazoles / pharmacology
  • Indoles / administration & dosage
  • Indoles / pharmacology
  • Injections, Intravenous
  • Intestinal Absorption / drug effects*
  • Intestinal Absorption / physiology
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / metabolism
  • Intestines / drug effects*
  • JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Lipopolysaccharides / pharmacology
  • Male
  • Maleimides / administration & dosage
  • Maleimides / pharmacology
  • Microvilli / drug effects
  • Microvilli / metabolism
  • Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors
  • Peptides / administration & dosage
  • Peptides / pharmacology
  • Proteasome Inhibitors
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase Inhibitors / pharmacology
  • Pyridines / administration & dosage
  • Pyridines / pharmacology
  • RNA, Messenger / metabolism
  • Rabbits
  • Sepsis / metabolism
  • Sodium-Glucose Transporter 1 / metabolism
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology*
  • p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors

Substances

  • Anthracenes
  • Enzyme Inhibitors
  • Imidazoles
  • Indoles
  • Lipopolysaccharides
  • Maleimides
  • Peptides
  • Proteasome Inhibitors
  • Protein Kinase Inhibitors
  • Pyridines
  • RNA, Messenger
  • Sodium-Glucose Transporter 1
  • Tumor Necrosis Factor-alpha
  • pyrazolanthrone
  • IP 20
  • Cyclic AMP-Dependent Protein Kinases
  • Protein Kinase C
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • p38 Mitogen-Activated Protein Kinases
  • bisindolylmaleimide I
  • SB 203580
  • Galactose